4.8 Review

Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy

期刊

LANCET
卷 390, 期 10105, 页码 1888-1917

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(17)30788-2

关键词

-

资金

  1. International Society of Nephrology
  2. AbbVie Inc
  3. Akebia Therapeutics LLC
  4. Amgen
  5. AstraZeneca LP
  6. Boehringer Ingelheim-Lilly
  7. Danone Nutricia Research
  8. Janssen Canada
  9. Merck Global
  10. Regulus Therapeutics Inc.

向作者/读者索取更多资源

The global nephrology community recognises the need for a cohesive plan to address the problem of chronic kidney disease (CKD). In July, 2016, the International Society of Nephrology hosted a CKD summit of more than 85 people with diverse expertise and professional backgrounds from around the globe. The purpose was to identify and prioritise key activities for the next 5-10 years in the domains of clinical care, research, and advocacy and to create an action plan and performance framework based on ten themes: strengthen CKD surveillance; tackle major risk factors for CKD; reduce acute kidney injury-a special risk factor for CKD; enhance understanding of the genetic causes of CKD; establish better diagnostic methods in CKD; improve understanding of the natural course of CKD; assess and implement established treatment options in patients with CKD; improve management of symptoms and complications of CKD; develop novel therapeutic interventions to slow CKD progression and reduce CKD complications; and increase the quantity and quality of clinical trials in CKD. Each group produced a prioritised list of goals, activities, and a set of key deliverable objectives for each of the themes. The intended users of this action plan are clinicians, patients, scientists, industry partners, governments, and advocacy organisations. Implementation of this integrated comprehensive plan will benefit people who are at risk for or affected by CKD worldwide.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据